TTrialPathMatch Me to Trials
← Back to trials
RecruitingBreast Cancer

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Eligible age

18+ yrs

Accepts

All genders

Locations

29 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

Sponsor: AstraZeneca

Where it's recruiting

Alabama

Daphne

Arkansas

Springdale

California

Duarte · Fountain Valley · Glendale · Sacramento …

Colorado

Aurora · Denver

Connecticut

New Haven

Florida

Altamonte Springs · Jacksonville · Miami · Palm Bay …

Georgia

Atlanta

Hawaii

Honolulu

Illinois

Chicago · Decatur · Elmhurst · Naperville

Indiana

New Albany

Iowa

Des Moines

Kentucky

Lexington · Louisville

Source: ClinicalTrials.gov · NCT06103864 · last updated 2026-11-20

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With · TrialPath